We create high-quality medicines and make them accessible to people who need them. Global experts with a local presence, we think creatively and act practically. We develop innovative solutions that transform people’s lives, for a healthier world wherever we are.

Messages from the Board


5040.
quotemark graphic

The strategy we set out when Siggi joined Hikma in 2018 is delivering results. I would like to thank all of our employees, as well as our customers, suppliers, shareholders and other stakeholders as we look forward to continued success in 2021."

Said Darwazah Executive Chairman
5041.
quotemark graphic

We faced a year of challenges and opportunities in 2020. I am enormously proud of how adaptive and resilient our employees were in the face of a global pandemic and am grateful for their unwavering commitment to maintaining the supply of vital medicines for patients across our markets."

Sigurdur Olafsson Chief Executive Officer

Five reasons to invest in Hikma

We have a track record of creating value for our shareholders. By focusing on our strategic priorities and leveraging our strengths, we can build upon our success.

  

Our business model


Our business model enables us to respond to the many opportunities and challenges we face.

Our strategy


By focusing on our strategy, we will deliver sustainable growth over the long-term.

Our operations

Our Injectables business develops and manufactures generic injectable products. Our products are sold across our markets and are primarily used in hospitals.

Core revenue ($m)


42% of Group revenue (2019: 40%)

Our Generics business develops and manufactures oral and other non-injectable generic products. Our products are sold in the US retail market.

Revenue ($m)


32% of Group revenue (2019: 33%)

Our Branded business develops and manufactures branded generics and markets and sells in-licensed patented products in MENA. Our products are sold in the retail and hospital markets.

Revenue ($m)


26% of Group revenue (2019: 26%)